Market Overview:
The global chlamydia infection therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chlamydia infections, rising demand for novel therapies, and growing awareness about sexually transmitted diseases (STDs). The global chlamydia infection therapeutics market is segmented on the basis of type into macrolides, quinolones, sulfonamides, tetracycline, aminopenicillins and others. Quinolones are expected to witness the highest growth during the forecast period owing to their high efficacy against Chlamydia trachomatis infections. On the basis of application, hospital pharmacies are expected to account for a major share of this market due to increased use of antibiotics in hospitals. However, drugstores are projected to register higher CAGR during 2018-2030 owingto growing demand for self-medication and home care products.
Product Definition:
Chlamydia infection is a sexually transmitted disease caused by the bacterium Chlamydia trachomatis. The most common symptoms are urethritis (inflammation of the urethra), cervicitis (inflammation of the cervix), and pelvic inflammatory disease. Chlamydia can also cause conjunctivitis, pneumonia, and infertility. Antibiotics are used to treat chlamydia infections.
Macrolides:
Macrolides are antibiotics that are derived from the fermentation of a microorganism, and they act by inhibiting the bacterial cell wall. They have a wide spectrum of antimicrobial activity against gram-positive and negative bacteria. Macrolides can be administered in two ways: topically as gels or solutions applied to the skin, or systemically via oral administration.
Quinolones:
Quinolones are antibiotics derived from natural products. They are characterized by a quinoline structure and can be divided into three groups, namely, benzyl derivatives (clindamycin), hydroxyquinolines (hydroxychloroquine), and chloroethylene derivatives (ciprofloxacin). All these agents have activity against gram-positive as well as negative bacteria.
Application Insights:
Based on the application, the global chlamydia infection therapeutics market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and drugstores and other applications. Hospital pharmacies held a major share in 2017 owing to factors such as high patient admissions rate in hospitals coupled with rising prevalence of chlamydia infections. According to estimates published by WHO, around 10 million people are diagnosed with Chagas disease every year globally.
Drugstores are expected to be the fastest-growing segment over the forecast period due to increasing awareness about preventable diseases among general public coupled with growing demand for cost-effective drugs that do not require expensive manufacturing process or R&D investment.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of chlamydia infections, rising number of treatment options, and increasing demand for cost-effective drugs are some factors driving the regional market. The U.S., which is one of the most affected countries by this disease, has a well-established healthcare infrastructure that makes it an attractive destination for pharmaceutical companies to invest in R&D activities related to novel therapies for chlamydia infections.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure and economic development in emerging markets such as India and China. Furthermore, these countries have a large population base suffering from chronic diseases such as STD's & HIV/AIDS that need effective treatment methods; thus offering lucrative opportunities for industry players over next eight years or so (until 2030).
Growth Factors:
- Increasing incidence of chlamydia infection: The global incidence of chlamydia is increasing at a rapid pace. This is primarily attributed to the changing sexual behavior and lack of awareness about the disease among people. Chlamydia infection is one of the most common sexually transmitted infections, which can lead to serious health complications if left untreated. Thus, there is a growing demand for effective therapeutics for the treatment of chlamydia infection.
- Growing prevalence of antibiotic-resistant strains: The prevalence of antibiotic-resistant strains of chlamydia is on the rise across the world. This has created a need for novel and more effective therapies for treating this disease. Chlamydia Infection Therapeutics market players are focusing on developing novel drugs that can effectively treat antibiotic-resistant strains of this disease.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chlamydia Infection Therapeutics Market Research Report
By Type
Macrolides, Quinolones, Sulfonamides, Tetracycline, Aminopenicillins, Others
By Application
Hospital Pharmacies, Drugstores, Retail Pharmacies, Online Pharmacies
By Companies
BD Medical, Bio Rad Laboratories, Siemens AG, Thermo Fisher Scientific, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher Corporation, BioMerieux, DiaSorin SpA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Chlamydia Infection Therapeutics Market Report Segments:
The global Chlamydia Infection Therapeutics market is segmented on the basis of:
Types
Macrolides, Quinolones, Sulfonamides, Tetracycline, Aminopenicillins, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Drugstores, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BD Medical
- Bio Rad Laboratories
- Siemens AG
- Thermo Fisher Scientific
- Novartis AG
- F Hoffmann-La Roche
- Abbott Laboratories
- Danaher Corporation
- BioMerieux
- DiaSorin SpA
Highlights of The Chlamydia Infection Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Macrolides
- Quinolones
- Sulfonamides
- Tetracycline
- Aminopenicillins
- Others
- By Application:
- Hospital Pharmacies
- Drugstores
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chlamydia Infection Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chlamydia Infection Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of Chlamydia infections. The company's lead product candidate, REGN-1005, is an orally available drug that is designed to treat chlamydial pneumonia.
Some of the major companies in the chlamydia infection therapeutics market are BD Medical, Bio Rad Laboratories, Siemens AG, Thermo Fisher Scientific, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher Corporation, BioMerieux, DiaSorin SpA.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chlamydia Infection Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chlamydia Infection Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chlamydia Infection Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chlamydia Infection Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chlamydia Infection Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Chlamydia Infection Therapeutics Market Size and Y-o-Y Growth
4.5.2 Chlamydia Infection Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Chlamydia Infection Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chlamydia Infection Therapeutics Market Size Forecast by Type
5.2.1 Macrolides
5.2.2 Quinolones
5.2.3 Sulfonamides
5.2.4 Tetracycline
5.2.5 Aminopenicillins
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chlamydia Infection Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chlamydia Infection Therapeutics Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Drugstores
6.2.3 Retail Pharmacies
6.2.4 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chlamydia Infection Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chlamydia Infection Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chlamydia Infection Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Chlamydia Infection Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chlamydia Infection Therapeutics Market Size Forecast by Type
9.6.1 Macrolides
9.6.2 Quinolones
9.6.3 Sulfonamides
9.6.4 Tetracycline
9.6.5 Aminopenicillins
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chlamydia Infection Therapeutics Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Drugstores
9.10.3 Retail Pharmacies
9.10.4 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chlamydia Infection Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Chlamydia Infection Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chlamydia Infection Therapeutics Market Size Forecast by Type
10.6.1 Macrolides
10.6.2 Quinolones
10.6.3 Sulfonamides
10.6.4 Tetracycline
10.6.5 Aminopenicillins
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chlamydia Infection Therapeutics Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Drugstores
10.10.3 Retail Pharmacies
10.10.4 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chlamydia Infection Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chlamydia Infection Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chlamydia Infection Therapeutics Market Size Forecast by Type
11.6.1 Macrolides
11.6.2 Quinolones
11.6.3 Sulfonamides
11.6.4 Tetracycline
11.6.5 Aminopenicillins
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chlamydia Infection Therapeutics Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Drugstores
11.10.3 Retail Pharmacies
11.10.4 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chlamydia Infection Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Chlamydia Infection Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chlamydia Infection Therapeutics Market Size Forecast by Type
12.6.1 Macrolides
12.6.2 Quinolones
12.6.3 Sulfonamides
12.6.4 Tetracycline
12.6.5 Aminopenicillins
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chlamydia Infection Therapeutics Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Drugstores
12.10.3 Retail Pharmacies
12.10.4 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chlamydia Infection Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chlamydia Infection Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chlamydia Infection Therapeutics Market Size Forecast by Type
13.6.1 Macrolides
13.6.2 Quinolones
13.6.3 Sulfonamides
13.6.4 Tetracycline
13.6.5 Aminopenicillins
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chlamydia Infection Therapeutics Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Drugstores
13.10.3 Retail Pharmacies
13.10.4 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chlamydia Infection Therapeutics Market: Competitive Dashboard
14.2 Global Chlamydia Infection Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BD Medical
14.3.2 Bio Rad Laboratories
14.3.3 Siemens AG
14.3.4 Thermo Fisher Scientific
14.3.5 Novartis AG
14.3.6 F Hoffmann-La Roche
14.3.7 Abbott Laboratories
14.3.8 Danaher Corporation
14.3.9 BioMerieux
14.3.10 DiaSorin SpA
